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http://dx.doi.org/10.1016/j.ccell.2017.03.001SUMMARYThe transcription factor Meis1 drives myeloid leukemogenesis in the context of Hox gene overexpression
but is currently considered undruggable. We therefore investigated whether myeloid progenitor cells
transformed by Hoxa9 and Meis1 become addicted to targetable signaling pathways. A comprehensive
(phospho)proteomic analysis revealed that Meis1 increased Syk protein expression and activity. Syk upregu-
lation occurs through aMeis1-dependent feedback loop. By dissecting this loop, we show that Syk is a direct
target of miR-146a, whose expression is indirectly regulated by Meis1 through the transcription factor PU.1.
In the context of Hoxa9 overexpression, Syk signaling induces Meis1, recapitulating several leukemogenic
features of Hoxa9/Meis1-driven leukemia. Finally, Syk inhibition disrupts the identified regulatory loop, pro-
longing survival of mice with Hoxa9/Meis1-driven leukemia.Significance
Overexpression of the Hox andMeis1 genes triggers leukemogenesis, is associated with high-risk acute myeloid leukemia
(AML) and currently cannot be targeted by drugs. Through the integration of a multi-omics approach with functional ana-
lyses we elucidated the molecular mechanism of Meis1 function and identified a Meis1-dependent regulatory feedback
loop involving PU.1, miR-146a, and Syk. Transformation of myeloid progenitors with Hoxa9 and Meis1 induced addiction
to Syk activity, and Syk itself induced Meis1 expression and a Meis1 transcriptional program. Hence, our study identifies
Syk as a key regulator of Hoxa9/Meis1-driven AML and places it as a prime candidate for the clinical testing of Syk inhibitors
in AML treatment.
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INTRODUCTION is required for transformation of committed myeloid progenitorsAcute myeloid leukemia (AML) is an aggressive neoplastic dis-
ease characterized by enhanced proliferation, blocked differen-
tiation, and dysregulated apoptosis. AML appears to be driven
by cell populations exhibiting extensive self-renewal properties,
known as leukemia stem cells (LSCs). Despite an increased un-
derstanding of the genetic mutations driving the development of
AML, the molecular processes that govern these self-renewal
properties remain elusive (The Cancer Genome Atlas Research
Network, 2013).
A large body of data implicates Hox genes in this process (Ar-
giropoulos and Humphries, 2007). A central role for Hox genes in
AML is supported by the frequently elevated Hox gene expres-
sion in AML cells (Afonja et al., 2000; Kawagoe et al., 1999; Law-
rence et al., 1999). Hox gene overexpression is associated with
genetically defined AML subgroups. Subsets of AML with favor-
able genetic features, such as core-binding factor leukemias and
PML-RARa-positive leukemias, express low levels of Hox genes
(Drabkin et al., 2002; Lawrence et al., 1999; Valk et al., 2004). In
contrast, unfavorable genetic alterations, such as mixed-lineage
leukemia (MLL) fusions (for instance MLL-AF9 and MLL-ENL)
exhibit their transforming capacity largely through upregulation
of Hox genes (Krivtsov and Armstrong, 2007; Muntean and
Hess, 2012).
Among Hox genes, the Abd-B-type Hox genes (especially
Hoxa9) are central regulators of the primitive hematopoietic
compartment. Hoxa9 is preferentially expressed in primitive he-
matopoietic cells and is downregulated during differentiation
(Pineault et al., 2002; Sauvageau et al., 1994). A number of over-
expression studies have also shown that certain Hox genes and
Hox gene fusions have the ability to promote expansion of prim-
itive hematopoietic cells (Ohta et al., 2007; Sauvageau et al.,
1995). Similarly, Hoxa9 enhances hematopoietic stem cell
regeneration in vivo, ultimately leading to the development of
leukemia, albeit with a long latency (Thorsteinsdottir et al., 2002).
Meis1 is another critical regulator of LSCs that is often overex-
pressed in Hox-gene-driven leukemia (Kawagoe et al., 1999;
Lawrence et al., 1999). Although Meis1 alone is unable to pro-
mote self-renewal, it plays a role in establishing LSC potential
in MLL-rearranged leukemias (Wong et al., 2007). Moreover,
when combined with overexpression of a Hox gene or the
NUP98-Hox fusion gene, overexpression of Meis1 leads to a
massive acceleration of leukemia development (Kroon et al.,
1998; Pineault et al., 2004). Gene expression studies have iden-
tified a number of Meis1 target genes, some of which are critical
for leukemogenesis (Argiropoulos et al., 2008; Kuchenbauer
et al., 2008, 2011; Wang et al., 2006). One such target is the tyro-
sine kinase Flt3, which in combination with a NUP98-Hox fusion
gene accelerates leukemogenesis (Palmqvist et al., 2006; Wang
et al., 2005). However, Flt3 appears to be dispensable for Meis1-
induced leukemic transformation (Argiropoulos et al., 2008; Mor-
gado et al., 2007).
While several studies have focused on Meis1 target genes,
only a few have examined the intracellular signaling pathways
affected by Meis1 overexpression. These studies showed that
Meis1 enhances signaling through Akt and Erk (Argiropoulos
et al., 2008) and activates the MAP kinase and PI3K/Akt path-
ways (Gibbs et al., 2012), and that activation of Wnt signaling550 Cancer Cell 31, 549–562, April 10, 2017by Hoxa9 and Meis1 (Wang et al., 2010).
However, our understanding of the interplay between Hoxa9-
and Meis1-regulated genes, its impact on signaling pathways,
and its functional consequences remains limited. Because
Hoxa9 and Meis1 overexpression is frequent in high-risk AML
(Drabkin et al., 2002; Heuser et al., 2009; Zangenberg et al.,
2009), and because both factors are currently considered un-
druggable, we set out to elucidate the effects of combined
Hoxa9/Meis1 overexpression on intracellular signaling and to
investigate whether cells transformed by Hoxa9 and Meis1
become addicted to targetable signaling processes.
To this end, we integrated a multi-omics approach including
mass-spectrometry-based proteomics, phosphoproteomics,
and transcriptome profiling, with targeted functional cell-based
and in vivo analyses.
RESULTS
Meis1 Induces Syk Signaling in Hoxa9-Overexpressing
Myeloid Progenitors
To elucidate the molecular mechanisms underlying the contri-
bution of Meis1 to leukemogenesis, we employed a retroviral
transplantation model in which lineage-depleted mouse bone
marrow cells were transduced with an MSCV-Hoxa9-PGK-neo
construct, alone or in combination with an MSCV-Meis1-
IRES-YFP construct that induced a 22-fold overexpression
of Meis1 (Figure S1A). As reported by others, the transformed
cells could be cultured in vitro in the presence of interleukin-3
(IL-3)/IL-6/stem cell factor (SCF) and expressed the expected
immunophenotype characterized by the myeloid markers
Mac-1 and Gr-1 as well as c-Kit (Figure S1B) (Pineault et al.,
2005; Wang et al., 2005). When transplanted into irradiated
recipient mice, cells transduced with Hoxa9 (H) or Hoxa9/
Meis1 (H/M) gave rise to leukemia resulting in a median
overall survival of 114 and 41 days, respectively (p < 0.001;
Figure 1A). This difference in survival is in accordance with
previously published results and reflects the aggressiveness
of Hoxa9/Meis1-driven AML observed in patients (Kroon
et al., 1998).
Because mRNA expression levels only moderately correlate
with actual protein levels (Schwanhausser et al., 2011; Vogel
and Marcotte, 2012), we set out to analyze the consequences
of Meis1 expression on the cellular proteome by combining
stable isotope labeling by amino acids in cell culture (SILAC)
and mass spectrometry (Figure S1C). This quantitative protein
expression analysis of H and H/M cells allowed the reproducible
identification and quantification of 1,810 proteins in at least four
out of six biological replicates (Table S1).
Interestingly, two tyrosine kinases, focal adhesion kinase 2
(Ptk2b) and spleen tyrosine kinase (Syk), were among the most
upregulated proteins in H/M cells (Figures 1B and 1C). Overex-
pression of Syk in H/M cells was confirmed by immunoblotting
(Figure 1D). Notably, real-time qPCR and RNA sequencing
(RNA-seq) indicated that Syk was not upregulated at the
mRNA level in H/M cells (qPCR fold change 1.15; RNA-seq
fold change 1.13; Figure 1E), thus explaining why several inde-
pendent RNA expression analyses did not link Syk to Meis1 (Ar-
giropoulos et al., 2008, 2010; Huang et al., 2012; Wang et al.,
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B Figure 1. Meis1 Increases Syk Protein Levels
in Hoxa9-Driven Leukemia
(A) Kaplan-Meier survival curves of mice trans-
planted with either H- or H/M-transformed myeloid
progenitor cells (n = 11). The p value is from a
Mantel-Cox test.
(B) Volcano plot relating q values for differential
protein expression to average normalized SILAC
ratios from six biological replicates. Blue (higher
expression in H cells) and orange (higher expression
in H/M cells) dots indicate significantly regulated
proteins (q < 0.01).
(C) Heatmap of SILAC ratios for significantly differ-
entially expressed proteins in H and H/M cells
across the six biological replicates.
(D) Syk protein expression in H and H/M cells by
immunoblotting. Actin was used as loading control
for relative protein quantification.
(E) Relative Syk mRNA expression as measured by
qPCR, normalized to GAPDH expression (mean ±
SD, n = 3); ns, not significant (two-sided unpaired
t test).
(F and G) Immunohistochemical staining of HOXA9,
MEIS1, and SYK in bone marrow biopsies from
patients with AML. SYK expression levels were
analyzed in 21 AML cases with high HOXA9
expression (F) and 28 cases with high HOXA9/
MEIS1 expression (G). Proportions of SYK expres-
sion levels as determined by two independent pa-
thologists using a three-stage staining score are
shown. See also Figure S1, Tables S1, and S2.2005, 2006; Wilhelm et al., 2011). To test whether the combined
H/M overexpression is also associated with enhanced Syk pro-
tein expression in primary human AML samples, we performed
immunohistochemical (IHC) analyses for HOXA9, MEIS1, and
SYK on a cohort of 115 AML cases (Table S2). We found overex-
pression of HOXA9 alone in a total of 21 cases and overexpres-
sion of both HOXA9 and MEIS1 in 28 cases, with only one Flt3-
ITD-positive patient. Increased SYK expression was significantly
more frequent (>4 times, p = 0.01, Fisher’s exact test) in samples
with a high expression of HOXA9 and MEIS1 (46.4%) than in
HOXA9-overexpressing samples (9.5%) (Figures 1F and 1G).
This frequency is also >2 times higher than in HOXA9 and
MEIS1 double-negative samples (22.7%) (Figure S1D).
Hence, combined overexpression of Hoxa9 and Meis1 leads
to upregulation of Syk at the post-transcriptional level, and
elevated SYK expression is associatedwith HOXA9/MEIS1 over-
expression in human AML samples.
The deregulated expression of kinases prompted us to
examine the global impact of Meis1 overexpression on intracel-
lular signaling by a mass spectrometry-based phosphoproteo-
mic analysis of H and H/M cells. The analysis was performed af-
ter enrichment for phosphorylated tyrosine residues (pYome)and separately after enrichment for phos-
phoserine, threonine, and tyrosine resi-
dues (global phosphoproteome, GPome)
(Figure S2A). We identified and quantified
a total of 584 class I phosphorylation
events (p-events with a localization proba-
bility >75%) in the pYome and 3,305 class Ip-events in the GPome, of which 236 and 297 were differentially
regulated between H and H/M cells, respectively (Figures 2A
and S2B; Table S1). Notably, this analysis revealed enhanced
phosphorylation of the Syk-activating tyrosines Y624/625 and
dephosphorylation of the inhibitory tyrosine Y317 in H/M cells,
suggesting enhanced Syk signaling in H/M cells. This result is
furthermore supported by an enhanced tyrosine phosphorylation
of Stat5 and Btk, two effectors known to be activated by Syk
in AML and B cells, respectively (Carnevale et al., 2013; Oellerich
et al., 2013) (Figure 2A). Differential phosphorylation of Syk
and Btk was confirmed by immunoblotting (Figure 2B).
As Meis1 not only enhanced Syk protein expression, but also
increased its activation-inducing tyrosine phosphorylation in our
model system, we set out to validate this finding in our cohort of
primary AML samples. Therefore, we performed IHC analyses
for phosphorylated SYK (pY348, a Syk-activating p-site) in the
21 AML cases overexpressing HOXA9 alone and in the 28
cases overexpressing both HOXA9 and MEIS1 (Figures 2C and
2D). This analysis revealed a significant association between
strong SYK phosphorylation and HOXA9/MEIS1 overexpression
(35.7% of H/M samples) compared with samples in which only
HOXA9 was overexpressed (0% of H samples; p < 0.003,Cancer Cell 31, 549–562, April 10, 2017 551
AC
E F
D
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Cells
(A) Intensities of peptide peaks versus average
normalized SILAC ratios for p-sites identified by
a mass-spectrometric pYome analysis in two bio-
logical replicates. Blue and orange dots indicate
p-sites upregulated in H and H/M cells, respectively.
Selected p-sites are labeled.
(B) Validation of selected differential tyrosine phos-
phorylation events in H and H/M cells by immuno-
blotting. Actin was used as loading control for rela-
tive protein quantification.
(C and D) Immunohistochemical staining of phos-
pho-SYK (pY348) and SYK in bone marrow biopsies
from AML patients. pSYK levels were analyzed in 21
human AML cases with high HOXA9 expression (C)
and 28 cases with high HOXA9/MEIS1 expression
(D). Proportions of pSYK levels as determined by
two independent pathologists using a three-stage
staining score are shown.
(E and F) Kaplan-Meier survival analysis for event-
free survival (EFS) in which all AML patients with
complete clinical profiles (E) or H and H/M patients
only (F) were grouped by pSYK expression. The
number of patients at risk belonging to each cate-
gory is shown. The p value is from aMantel-Cox test.
See also Figure S2, Tables S1, and S2.Fisher’s exact test) or double-negative samples (13.6%; p =
0.024) (Figures 2C, 2D, and S2C).Moreover, high SYKphosphor-
ylation correlates with poor event-free and relapse-free survival
in the subset of AML patients with complete clinical profiles
within our cohort, both with and without stratification for H and552 Cancer Cell 31, 549–562, April 10, 2017H/M expression (Figures 2E, 2F, S2D, and
S2E). Together, these results indicate a
strong association of MEIS1 overexpres-
sion with upregulation and activation of
SYK in AML.
Enhanced Syk Activation Is Partly
Dependent on Integrin Beta 3
We next investigated potential mecha-
nisms of Syk activation in H/M cells. Syk
activation requires docking to phosphory-
lated immunoreceptor tyrosine-based acti-
vation motifs (ITAMs) (Kulathu et al., 2009).
Interestingly, our pYome analysis revealed
increased ITAM phosphorylation of the
common Fcg-chain Fcer1g in H/M cells
(Figure 2A). Fcer1g is an intracellular
signaling module that associates with Fc
receptors and integrins (Humphrey et al.,
2005). While depletion of Fc receptors
does not affect viability and proliferation
of AML cells, integrin beta 3 (Itgb3) is
required for leukemogenesis (Miller et al.,
2013; Oellerich et al., 2013). Notably,
Fcer1g interacts with Syk in H cells and, in
line with enhanced ITAM phosphorylation,
this interaction is stronger in H/M cells(Figure 3A). In addition, Meis1 overexpression in H cells
increased transcript levels of Fcer1g, Itgb3, and its heterodi-
meric partner integrin alpha v (Itgav), and upregulated Itgb3/It-
gav expression on the cell surface (Figures 3B and 3C). To test
whether increased Itgb3 cell surface expression translates into
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Figure 3. Syk Phosphorylation Is Partly Dependent on Integrin
Beta 3
(A) Co-immunoprecipitation of Fcer1g and Syk from H and H/M cells.
(B) Fcer1g, Itgb3, and Itgav expression estimated by normalized RNA-seq
counts.
(C) Itgb3 and Itgav cell surface expression in H andH/M cells measured by flow
cytometry. Unstained cells were used as controls.
(D) Itgb3 cell surface expression in H/M cells transduced with either a lentiviral
non-specific (nsp) control CRISPR or a CRISPR targeting Itgb3 (DItgb3).
(E) Corresponding (p)Syk expression determined by immunoblotting. Actin
was used as loading control for relative protein quantification.increased Syk activity, we knocked out Itgb3 using CRISPR/
Cas9 by transducing H/M cells with a lentiviral Itgb3 CRISPR
construct (DItgb3) (Figure 3D). Itgb3 knockout led to a 50%
reduction in activatory Syk phosphorylation (pY525/526) in a
polyclonal cell population (Figure 3E), indicating that enhanced
Syk activation in H/M cells depends, at least in part, on Itgb3.
Syk Expression Is Regulated by miR-146a
Because the upregulation of Syk in H/M cells was only detect-
able at the protein but not at the mRNA level (Figures 1B–1E),
and because no differences were detected in the proteasomal
degradation of Syk (data not shown), we reasoned that micro-RNAs (miRNAs) might be involved in the regulation of Syk. To
test this hypothesis, we globally profiled miRNA expression in
H and H/M cells (Figure 4A). This analysis identified eight signif-
icantly downregulated miRNAs in H/M cells potentially respon-
sible for the observed upregulation of Syk (Figures 4B and
S3A). To refine our candidate list, we retained only thosemiRNAs
that were predicted to target Syk by Targetscan (Agarwal et al.,
2015). The algorithm identified two predicted binding sites for
miR-146a in the 30 UTR of Syk. A significant downregulation of
mmu-miR-146a and pri-miR-146a in H/M relative to H cells
was further confirmed by qPCR (Figures 4C and 4D).
To experimentally validate targeting of Syk by miR-146a, we
performed luciferase assays using two reporter constructs,
one containing two copies of both predicted miR-146a binding
sites (or mutated versions as controls; Figure 4E) and one con-
taining the full-length Syk 30 UTR (Figure 4F). Overexpression
of miR-146a precursor (pre-miR-146a) decreased luciferase ac-
tivity in lysates of HEK293T cells transfected with the construct
containing the miR-146a target sites or the Syk 30 UTR, but
had no effect on the construct with mutated binding sites (Fig-
ures 4E and 4F). This result indicates that Syk is a direct miR-
146a target.
To further test whether miR-146a affects Syk expression, we
knocked out miR-146 using CRISPR/Cas9 by transducing
H cells with a lentiviral miR-146-specific CRISPR construct
(DmiR-146) that reducedmiR-146a expression by 75% in a poly-
clonal cell population (Figure 4G) or isolated myeloid progenitor
cells from B6/miR-146a/ mice and transduced them with
Hoxa9. The CRISPR-mediated knockout of miR-146 led to a
2.9-fold increase in the protein expression of Syk (Figure 4H),
increased cell proliferation (Figures 4I and S3B), reduced
apoptosis (Figure S3C), and enhanced c-Kit expression (Fig-
ure S3D), mirroring the phenotype of H/M cells. Finally, mice
transplanted with miR-146 knockout H cells exhibited acceler-
ated leukemia development compared with mice transplanted
with H cells (Figure 4J).
In summary, our data strongly indicate that upregulation of Syk
in H/M cells is mediated by downregulation of miR-146a.
Meis1 Influences miR-146a Expression through
Downregulation of PU.1
Next, we investigated the molecular mechanism by which Meis1
downregulates miR-146a. No Meis1 binding site was found in
the vicinity of the miR-146a locus in published Meis1 chromatin
immunoprecipitation sequencing (ChIP-seq) profiles in myeloid
cells (Heuser et al., 2011; Huang et al., 2012) (Figure S4A). How-
ever, miR-146a is known to be regulated by PU.1 (Spi1) in mac-
rophages (Ghani et al., 2011). Therefore, we examined the bind-
ing of PU.1 to a previously identified PU.1 binding site located 10
kb upstream (10 kb) of miR-146a by ChIP-qPCR. This region
exhibits epigenomic features of an active promoter, including
an enrichment for H3K4me3 and binding of RNA polymerase II
in ENCODE data (Encode Project Consortium, 2012) (Fig-
ure S4B). We found that PU.1 binding to the 10 kb site was
significantly reduced in H/M compared with H cells (Figure 5A),
suggesting that decreased PU.1 binding might be responsible
for the downregulation ofmiR-146a. Consistent with this finding,
we also detected lower PU.1 protein and mRNA levels in H/M
compared with H cells (Figures 5B, 5C, and 6F). In addition, anCancer Cell 31, 549–562, April 10, 2017 553
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Figure 4. Syk Is a Direct Target of miR-146a
(A) Schematic workflow of the miRNA expression analysis in H- and H/M-transformed myeloid progenitors.
(B) Volcano plot relating q values for differential miRNA expression between H and H/M cells to average miRNA expression fold-changes from three biological
replicates. Blue (higher expression in H cells) and orange (higher expression in H/M cells) dots indicate significantly regulated miRNAs (q < 0.01).
(C and D) Relative mmu-miR-146a expression (C) and pri-miR-146a expression (D) in H/M versus H cells, measured by qPCR and normalized to sno202 and
GAPDH expression, respectively (mean ± SD, n = 3). The p values are from a two-sided unpaired t test.
(E) Luciferase assay validating binding of miR-146a to the predicted target sites within the 30 UTR of Syk (mean ± SD, n = 4); WT, predicted miR-146a target
sequence; MUT, mutated version thereof. The p values are from a two-sided unpaired t test. ns, not significant.
(F) Luciferase assay validating binding of miR-146a to the full-length Syk 30 UTR (mean ± SD, n = 4). The p value is from a two-sided unpaired t test.
(G) Left, secondary structure of mmu-miR-146 as predicted by RNAfold (Lorenz et al., 2011). The CRISPR/Cas9 cleavage site is indicated. Right, relative
expression of miR-146a,measured by qPCR and normalized to sno202 expression, in H cells transduced with either a lentiviral non-specific (nsp) control CRISPR
or a CRISPR targeting miR-146 (DmiR-146) (mean ± SD, n = 3). The p value is from a two-sided unpaired t test.
(H) Corresponding Syk protein expression by immunoblotting. Actin was used as loading control for relative protein quantification.
(I) Cell-proliferation curves for H cells transducedwith either a lentiviral non-specific (nsp) control CRISPR or a CRISPR targetingmiR-146 (DmiR-146) (mean ± SD,
n = 3).
(J) Kaplan-Meier survival curves ofmice transplantedwith H or H/M cells transducedwith a lentiviral non-specific (nsp) control CRISPR, or with H cells transduced
with a CRISPR targeting miR-146 (DmiR-146) (n = 7). The p value is from a Mantel-Cox test. See also Figure S3.
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B C Figure 5. Meis1 Downregulates miR-146a
through PU.1
(A) Fold enrichment of PU.1 binding over IgG con-
trol as measured by ChIP-qPCR in H and H/M cells
(mean ± SD, n = 3). The miR-146a 10 kb region
spans the transcription start site of the miR-146a
host gene; ns, not significant.
(B) PU.1 protein expression in H and H/M cells by
immunoblotting. Histone H3 was used as loading
control for relative protein quantification.
(C) Relative PU.1 mRNA expression in H versus
H/M cells measured by qPCR and normalized to
GAPDH expression (mean ± SD, n = 3).
(D and E) Immunohistochemical staining of PU.1 in
bone marrow biopsies from patients with AML.
PU.1 expression levels were analyzed in 21 AML
cases with high HOXA9 expression (D) and 28 ca-
ses with high HOXA9/MEIS1 expression (E). Pro-
portions of PU.1 expression levels as determined
by two independent pathologists using a three-
stage staining score are shown.
(F) PU.1 and SYK protein expression by immuno-
blotting in H cells transfected with either a control
shRNA (nsp) or an shRNA targeting PU.1 (KD).
Tubulin was used as loading control for relative
protein quantification.
(G) mmu-miR-146a and pri-miR-146a expression
as measured by qPCR after PU.1 knockdown (KD)
relative to control shRNA (nsp) (mean ± SD, n = 4).
The p values are from a two-sided unpaired t test.
See also Figure S4 and Table S2.Integrated Motif Activity Response Analysis based on tran-
scriptome profiles of H and H/M cells indicated decreased
PU.1 activity in H/M relative to H cells (Figure S4C).
Moreover, we found a significant association between low or
no PU.1 protein expression and high expression of HOXA9 and
MEIS1 (78.2% compared with 10% for HOXA9-overexpressing
samples, p < 9 3 106, Fisher’s exact test) in our AML patient
cohort (Figures 5D and 5E). Finally, a 55% knockdown of PU.1
in H cells reduced miR-146a expression and increased Syk pro-
tein levels (Figures 5F and 5G). Taken together, these data indi-
cate that, by acting through PU.1, Meis1 indirectly influences the
expression of miR-146a.
Syk Overexpression Triggers a Meis1-Dependent
Transcriptional Program
We next sought to characterize the functional consequences of
Syk overexpression in the context of Hoxa9-driven leukemias.
For this purpose, we examined the consequences of a lentiviral
overexpression of human SYK (hSYK) in H cells in vitro and
in vivo. Of note, Syk expression levels were comparable
between H/M cells and cells overexpressing Hoxa9 and
hSYK (H/S) (Figures S5A and S5B). hSYK overexpression re-
sulted in enhanced cell proliferation rates in the presence of
IL-3, IL-6, and SCF, mimicking the overexpression of Meis1C(Figure 6A). In addition, it enhanced the
colony-formation capacity and replating
efficiency of H cells in colony assays;
both features suggest increased self-
renewal (Figure S5C).While Hoxa9 alone is sufficient to enable replating, both Meis1
and hSYK enhanced replating efficiency. This ability was signif-
icantly reduced by the Syk inhibitor R406, which decreased
replating efficiency of H/M and H/S cells while moderately
affecting colony formation and replating efficiency of H cells
(Figure S5C).
We next investigated whether hSYK overexpression affected
the leukemogenicity of H cells upon transplantation into lethally
irradiated recipient mice. We found that the combination of
Hoxa9 and hSYK significantly increased the aggressiveness of
the leukemias compared with Hoxa9 alone (median of 38.5
versus 103.5 days; p < 0.001), with a median survival remarkably
similar to that of Hoxa9/Meis1 (39 days; Figures 6B and S5P).
The observed leukemias were classified as AML with a dense
infiltration of leukemic blasts in the bone marrow, spleen, and
liver, and leukemic blasts in the peripheral blood (Figures S5D–
S5M). Leukemias induced by the combination of Hoxa9 with
hSYK or Hoxa9 with Meis1 were characterized by lower leuko-
cyte counts and a more pronounced anemia compared with
Hoxa9 alone (Figure S5N). Immunophenotyping showed that
the leukemic cells expressed c-Kit and the myeloid antigens
Gr-1 and Mac-1, in agreement with previously published immu-
nophenotypes of Hoxa9/Meis1-driven AML (Kroon et al., 1998).
In addition, the frequency of c-Kit-positive cells was higher forancer Cell 31, 549–562, April 10, 2017 555
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B Figure 6. Syk Overexpression Mimics the
Leukemogenic Meis1 Transcriptional Pro-
gram in Hoxa9-Driven Leukemia
(A) Proliferation curves for H, H/M and H/S cells
(mean ± SD, n = 4).
(B) Kaplan-Meier survival curves ofmice transplanted
with either H (n = 9), H/M (n = 10) or H/S (n = 11) cells.
The p values are from a Mantel-Cox test.
(C) Summary of differentially expressed (DE) protein-
coding genes and lincRNAs (Benjamini-Hochberg
adjusted p value % 0.001, Wald test) in H-trans-
formed myeloid progenitors upon overexpression of
Meis1 (upper panel) and SYK (lower panel).
(D) Gene expression correlation between H/M and
H/S cells. Only genes that were significantly differ-
entially expressed in at least one condition (Benja-
mini-Hochberg adjusted p value % 105, likelihood
ratio test) were considered. Correlation value (r) is
Spearman’s rank correlation coefficient.
(E) Hierarchical clustering of the top 50 differentially
expressed genes. Regularized log2 expression
values are row-mean subtracted.
(F) Meis1 and PU.1 expression estimated by
normalized RNA-seq counts. Black lines denote the
median.
(G) Apoptosis analysis of H/S cells derived from
either C57BL/6J mice or inducible Meis1 knockout
mice, based on Annexin V/7-AAD staining (mean ±
SD, n = 3). Cells were treated with either ethanol
(EtOH, control) or 4-hydroxytamoxifen (4-OHT). The
p values are from a two-sided unpaired t test. See
also Figure S5.Hoxa9 and Meis1, and for Hoxa9 and hSYK, compared with
Hoxa9 alone (Figure S5O), suggesting a more immature pheno-
type of the developing leukemias.
SYK activation depends on the phosphorylation of Y348 and
Y352 (Kulathu et al., 2009). To test whether the accelerated leu-
kemia development exhibited by H/S cells is dependent on SYK
activation, we transplanted H cells expressing either hSYK or a
hSYK Y348F/Y352F double mutant into lethally irradiated recip-556 Cancer Cell 31, 549–562, April 10, 2017ient mice and monitored overall survival.
Notably, hSYK double mutant abrogated
the enhanced leukemogenicity of H/S cells
(Figure S5P), indicating that SYK activation
is necessary for this feature.
The striking phenotypic similarity be-
tween H/M and H/S cells led us to compare
the transcriptional consequences of Meis1
and hSYK overexpression in Hoxa9-trans-
formed myeloid progenitors by RNA-seq.
By analyzing protein-coding and non-cod-
ing transcriptome compartments, we found
that both Meis1 and hSYK profoundly alter
the transcriptome of H cells, leading to the
differential expression of thousands of pro-
tein-coding genes and >100 long intergenic
non-coding RNAs (lincRNAs; Figures 6C,
S6A, and S6B). Intriguingly, these tran-
scriptional changes were highly correlated
(r = 0.823) between H/M and H/S cells(Figure 6D), which share a common transcriptional signature (Fig-
ures6EandS6B).Moreover, hSYK inducedexpressionofMeis1 to
levels comparablewith those inH/M cells (Figure 6F) and differen-
tially expressedgenes inH/MandH/Scellsweresimilarly enriched
for direct Meis1 binding to their promoter regions (Huang et al.,
2012) (Figure S6C). Importantly, Meis1 expression is necessary
for survival of H/S cells, as an inducible Meis1 knockout signifi-
cantly affected H/S cell viability (Figures 6G and S6D).
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Figure 7. Meis1 Sensitizes Hoxa9-Driven Leukemia to Syk Inhibition
(A) Syk protein expression in H/M cells transfected with either a control shRNA (GL2) or two shRNAs targeting Syk. Actin was used as loading control for relative
protein quantification.
(B) Percentage of BFP-positive shRNA-expressing cells relative to BFP-negative shRNA-negative cells at the times indicated (mean ± SD, normalized to day 0,
n = 3).
(C) Same as (A), before and after 5 days of doxycycline (dox) treatment in vivo.
(D) Kaplan-Meier survival curves of mice transplanted with H/M cells and treated with doxycycline for 43 days to express non-specific control and Syk-specific
shRNA (n = 8). The p value is from a Mantel-Cox test.
(E) Percentage of YFP-positive cells from peripheral blood of mice transplanted with H (left) or H/M (right) cells after treating for 7 days with R788 or placebo.
Measurements were taken at the indicated time points. The black line connects median values.
(F) Kaplan-Meier survival curves of mice transplanted with either H or H/M cells and treated for 20 days with R788 or placebo (n = 11). The p value is from aMantel-
Cox test.
(G) Relative HOXA9 andMEIS1mRNA expression in MV4-11 and KG1 cell lines, and in patient-derived AML cells as measured by qPCR, normalized to GAPDH
expression (mean ± SD, n = 3).
(H) (p)SYK expression in the patient-derived AML cells in (G). Actin was used as loading control for relative protein quantification. avg, average.
(I) Half maximal inhibitory concentration (IC50) for R406 (left) and PRT062607 (right) in patient-derived AML cells as determined by an Annexin V/7-AAD apoptosis
assay. Cells were treated for 24 hr and DMSO was used as a control (n = 3). Representative dose-response curves for AML no. 1 (HOXA9 high, MEIS1 low) and
AML no. 5 (HOXA9 high, MEIS1 high) are shown at the top. Ticks correspond to estimated IC50 values.
(legend continued on next page)
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Together, these results indicate that Meis1 and Syk regu-
late highly overlapping transcriptional programs and implicate
Meis1 as an effector of Syk signaling to chromatin.
Hoxa9/Meis1-Overexpressing Myeloid Progenitors Are
Syk Dependent
To test whether the enhanced Syk signaling observed in H/M
cells could be exploited therapeutically, we analyzed the effects
of Syk inhibitors and of a small hairpin RNA (shRNA)-mediated
knockdown of Syk in H/M cells, in vitro and in vivo. As shown
above, the Syk inhibitor R406 significantly reduced colony-
formation potential and replating efficiency in H/M cells
(Figure S5C).
We further examined the effect of Syk inhibition in H and H/M
cells by monitoring the fate of individual cells and their progeny
by time-lapse microscopy and single-cell tracking (Rieger
et al., 2009). This allowed us to track hundreds of H andH/Mcells
over more than 50 hr in real time and to record their history
across cell generations. Our analysis revealed a significant in-
crease in cell death in R406-treated H/M cells compared with
DMSO-treated cells, whereas H cells were not significantly
affected (Figure S6E). These results are not mediated by off-
target effects of R406, as knocking down Syk in H/M cells with
a doxycycline-inducible lentiviral shRNA resulted in decreased
cell viability in vitro (Figures 7A and 7B). In addition, we knocked
down Syk in vivo by transplanting mice with cells that were either
transduced with the doxycycline-inducible lentiviral Syk shRNAs
or with control shRNAs and treating them with doxycycline for
43 days. Knockdown of Syk prolonged the survival of mice trans-
planted with H/M cells from a median time of 40.5 days in con-
trols to a median of 103 days (p < 0.001) (Figures 7C and 7D).
Furthermore, we treated mice transplanted with H/M or H cells
with the oral Syk inhibitor R788, a prodrug of R406. Seven
days of treatment with R788 reduced the percentage of leukemic
cells in mice transplanted with H/M cells by more than 70% on
average, while barely affecting the level of H cells (Figure 7E).
Treatment with R788 for 20 days significantly prolonged the sur-
vival of mice transplanted with H/M cells from a median of
38 days to a median of 130 days (p < 0.001; Figure 7F). No sig-
nificant effect was observed in mice transplanted with H cells.
Given the pronounced sensitivity of Hoxa9/Meis1-trans-
formed mouse hematopoietic progenitors to Syk inhibition, we
examined whether this effect can also be recapitulated in pri-
mary human AML samples. For this purpose, we considered
three AML samples exhibiting strong HOXA9 expression and
weak MEIS1 expression, and compared them with three sam-
ples expressing both genes at high levels (Figure 7G). Notably,
none of these samples harbored activating mutations in FLT3.
We found that AML samples expressing high levels of both
HOXA9 and MEIS1 exhibited increased expression of SYK
and pSYK, and were more sensitive to the SYK inhibitors
PRT062607 and R406 compared with samples with weak
MEIS1 expression (Figures 7H–7I). Importantly, Syk inhibition(J) Relative viability of CD34+ bone marrow cells from healthy donors. Cells were t
inhibitors in H cells.
(K) Kaplan-Meier survival curves of NSG mice transplanted with patient-derived A
AML no. 1 and 5; n = 5 for AML no. 2 and 6). The p values are from a Mantel-Co
558 Cancer Cell 31, 549–562, April 10, 2017did not affect the viability of CD34+ progenitor cells isolated
from healthy donors (Figure 7J). Finally, Syk inhibition signifi-
cantly prolonged survival of NSG mice transplanted with pa-
tient-derived AML cells overexpressing HOXA9 and MEIS1,
with no significant difference for HOXA9 alone (Figure 7K).
In summary, our results demonstrate that enhanced Syk
signaling in the presence of Meis1 represents a regulatory feed-
back mechanism of leukemogenesis in Hoxa9-driven AML that
renders these cells sensitive to Syk inhibition.
DISCUSSION
Several studies characterized gene expression signatures and
individual target genes regulated by Hoxa9 and Meis1. Among
those, only a few at most partially recapitulate the oncogenic ef-
fects of Hoxa9 and Meis1.
In this work, we employed quantitative mass spectrometry to
study proteomic and phosphoproteomic changes induced by
Meis1 overexpression, identify Meis1-regulated proteins and
signaling pathways, and investigate their therapeutic potential.
By this approach we identified upregulation and activation of
Syk by Meis1 as a key leukemogenic mechanism in a Hoxa9-
driven mouse model system and in a subset of human AMLs.
Syk was originally described as a signaling mediator down-
stream of the B cell antigen receptor, but it has also been iden-
tified as a drug target for the treatment of AML (Hahn et al.,
2009). In addition, Syk has been shown to be activated by integ-
rin signaling, to phosphorylate STAT5 in AML (Miller et al., 2013;
Oellerich et al., 2013) and to cooperate with FLT3-ITD during the
induction andmaintenance of myeloid leukemias (Puissant et al.,
2014). Moreover, SYKY323 phosphorylation in AML has recently
been correlated with an unfavorable prognosis (Boros et al.,
2015), and activatory SYK phosphorylation (pY348) correlates
with poor event-free and relapse-free survival in our AML patient
cohort.
Our results indicate that Syk protein levels, but not mRNA
levels, are upregulated upon overexpression of Meis1 through
a post-transcriptional mechanism. By analyzing Meis1-depen-
dent miRNA expression changes, we found that Meis1 downre-
gulates miR-146a, which in turn regulates Syk expression post-
transcriptionally. We have thereby identified a regulatory link
between miR-146a and Syk that is indirectly orchestrated by
Meis1. Similar regulatory paradigms may have implications for
cell types other than myeloid.
miR-146a has been previously identified as an important regu-
lator of myeloid differentiation in the context of myelodysplastic
syndrome (MDS), where it targets TRAF6 (Starczynowski et al.,
2010). Since miR-146a is located on chromosome 5q, it remains
to be determined whether deregulated Syk expression could
also play a role in the pathogenesis of MDS with 5q deletion.
Interestingly, miR-146a has also been described as an impor-
tant regulator of monocytic/macrophage development down-
stream of the myeloid transcription factor PU.1 (Ghani et al.,reated with either R406 or PRT062607. Blue lines indicate the IC50 for both SYK
ML cells indicated in (G) and treated for 14 days with R788 or vehicle (n = 6 for
x test. See also Figure S6.
2011). This observation linksmiR-146a tomyeloid differentiation,
which is dysregulated in leukemic transformation. In our model
system, overexpression of Meis1 reduces PU.1 occupancy at
the putative promoter region of the miR-146a host gene. In addi-
tion, a global downregulation of PU.1 target genes suggests
reduced PU.1 activity genome-wide. This can be partially ex-
plained by reduced PU.1 expression in H/M cells.
PU.1 has a dual role in the development of leukemia. On the
one hand, it is required for themaintenance of MLL-driven leuke-
mias (Aikawa et al., 2015; Zhou et al., 2014). On the other hand,
graded reduction of PU.1 levels, not ablation of PU.1, has been
identified as amechanism of leukemic transformation in both hu-
man and mouse model systems (Rosenbauer et al., 2004, 2005;
Will et al., 2015). The importance of PU.1 dysregulation is further
underscored by the identification of PU.1-inactivating mutations
in human MLL-rearranged AML (Lavallee et al., 2015). Our data
link Meis1 overexpression to PU.1 downregulation, suggesting
that attenuated PU.1 activity might be a functionally relevant
feature of Hox/Meis-driven AML.
Our results implicate Syk in Meis1-mediated leukemic trans-
formation. Syk potently cooperates with Hoxa9 for leukemic
transformation and is strikingly similar to Meis1 with regard to
its leukemogenic potential. This similarity is furthermore under-
scored by the ability of Syk to induce aMeis1 transcriptional pro-
gram in the context of Hoxa9 overexpression. Notably, Syk does
not render Hoxa9-transformed cells independent of Meis1, indi-
cating a cell-intrinsic dependency.
Meis1 enhances Syk expression through a regulatory feed-
back circuit. In addition, Meis1 also upregulates the Syk
activator Itgb3 and downregulates the phosphatase Ptpn6
(log fold change = 0.345, Benjamini-Hochberg adjusted
p = 2.88 3 1017; H/M versus H cells), a known negative regu-
lator of Syk activity. Additional signaling effectors that might
contribute to Syk activation in our circuit remain to be identified.
The largely overlapping transcriptional consequences of Syk
and Meis1 led us to hypothesize that Meis1-transformed leuke-
mias would be more addicted to Syk than to other signaling pro-
teins such as Flt3, which has previously been shown to be
dispensable for Meis1-driven leukemias (Morgado et al., 2007).
Our orthogonal treatment results, based on both shRNA-medi-
ated knockdown and pharmacological inhibition of Syk, showed
that Hoxa9/Meis1-transformed leukemias were clearly more
sensitive to Syk inhibition than Hoxa9-transformed leukemias.
In summary, we have identified a Meis1-dependent feedback
loop involving PU.1, miR-146a, and Syk that promotes cell sur-
vival and can be targeted by Syk inhibitors. Therefore, Hoxa9/
Meis1-overexpressing AML is a prime candidate for exploring
the therapeutic potential of Syk inhibition.STAR+METHODS
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NE-PER Nuclear and Cytoplasmic Extraction Reagents Thermo Fisher Scientific Cat# 78833
Pierce BCA Protein Assay Kit Thermo Fisher Scientific Cat# 23227
RevertAid H Minus First Strand cDNA Synthesis Kit Thermo Fisher Scientific Cat# K1632
SuperSignal West Femto Maximum Sensitivity Substrate Thermo Fisher Scientific Cat# 34096
TaqMan MicroRNA Reverse Transcription Kit Thermo Fisher Scientific Cat# 4366596
TaqMan Universal Master Mix II, with UNG Thermo Fisher Scientific Cat# 4440038
TURBO DNA-free Kit Thermo Fisher Scientific Cat# AM1907
TaqMan MicroRNA Assay
hsa-miR-146a
Thermo Fisher Scientific Cat# 4427975
Assay ID: 000468
TaqMan MicroRNA Assay
Gapdh
Thermo Fisher Scientific Cat# 4331182
Assay ID: Mm99999915_g1
TaqMan MicroRNA Assay
Meis1
Thermo Fisher Scientific Cat# 4331182
Assay ID: Mm00487664_m1
TaqMan MicroRNA Assay
Spi1
Thermo Fisher Scientific Cat# 4331182
Assay ID: Mm00488140_m1
TaqMan MicroRNA Assay
snoRNA202
Thermo Fisher Scientific Cat# 4427975
Assay ID: 001232
Deposited Data
Mass spectrometry dataset This paper PRIDE Archive (PRIDE: PXD004192)
RNA-seq dataset This paper Short Read Archive (SRA: PRJNA322136)
miRNA microarray dataset This paper NCBI Gene Expression Omnibus
(GEO: GSE74566)
Experimental Models: Cell Lines
GP+E-86 (ATCC CRL-9642) ATCC Cat# CRL-9642
Platinum-E (Plat-E) Retroviral Packaging Cell Line Cell Biolabs, Inc. Cat# RV-101
293T DSMZ Cat# ACC 635
KG1 DSMZ Cat# ACC 14
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MV4-11 DSMZ Cat# ACC 102
Experimental Models: Organisms/Strains
B6.Cg-Mir146tm1.1Bal/J Jackson Laboratory Cat# 016239
B6;129-Gt(ROSA) 26Sortm1(Cre/ERT)Nat/
Meis1tmloxP/ tmloxP
Miller et al., 2016 N/A
C57BL/6J Jackson Laboratory Cat# 000664
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ Jackson Laboratory Cat# 005557
Oligonucleotides
Pre-miR miRNA Precursor hsa-miR-146a-5p Thermo Fisher Scientific Cat# AM17100
Asssay ID: PM10722
Pre-miR miRNA Precursor Negative Control #1 Thermo Fisher Scientific Cat# AM17110
shGL2
TGCTGTTGACAGTGAGCGCTGGCCTTATCTGCC
TCCTTAATAGTGAAGCCACAGATGTATTAAGGAG
GCAGATAAGGCCATTGCCTACTGCCTCGGA
Sigma-Aldrich N/A
shSyk-1
TGCTGTTGACAGTGAGCGCTGGCCTTATCTGC
CTCCTTAATAGTGAAGCCACAGATGTATTAAGG
AGGCAGATAAGGCCATTGCCTACTGCCTCGGA
Sigma-Aldrich N/A
shSyk-2
TGCTGTTGACAGTGAGCGATGGAATAATCTCA
AGGATCAATAGTGAAGCCACAGATGTATTGAT
CCTTGAGATTATTCCACTGCCTACTGCCTCGGA
Sigma-Aldrich N/A
hHOXA9 fwd
AAAACAATGCTGAGAATGAGAGC
Sigma-Aldrich N/A
hHOXA9 rev
TATAGGGGCACCGCTTTTT
Sigma-Aldrich N/A
hMEIS1 fwd
GCATGAATATGGGCATGGA
Sigma-Aldrich N/A
hMEIS1 rev
CATACTCCCCTGGCATACTTTG
Sigma-Aldrich N/A
hACTB fwd
TCCCTGGAGAAGAGCTACG
Sigma-Aldrich N/A
hACTB rev
GTAGTTTCGTGGATGCCACA
Sigma-Aldrich N/A
miR146a (1) fwd
CCACCTTAAAGCCAGCAGAG
Sigma-Aldrich N/A
miR146a(1) rev
CCTGACCAGCACTTCCTCAG
Sigma-Aldrich N/A
PU.1 -13.7 fwd
AGGCAGAGCACACATGCTTC
Sigma-Aldrich N/A
PU.1 -13.7 rev
CTTCTGGGCAGGGTCAGAGT
Sigma-Aldrich N/A
FLT3 exon9 fwd
TTTGCACTCGTAGCAAATGG
Sigma-Aldrich N/A
FLT3 exon9 rev
GTTCAGCTGCCAAAGAGAGG
Sigma-Aldrich N/A
Exon 7 CTL fwd
TTGGAATAGAGACCATGATGACAC
Sigma-Aldrich N/A
Exon 7 CTL rev
GTTATCCCCACTGTGTGAAGTATG
Sigma-Aldrich N/A
NDF fwd
AGCTTCATTTGAAGTTCCCTATTG
Sigma-Aldrich N/A
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NDF rev
TATTAGGTGGATCCAAGCTTCATT
Sigma-Aldrich N/A
DSA7/8 s
CACCGAGGAACTGTTCACCGCGGCG
Sigma-Aldrich N/A
DSA7/8 as
AAACCGCCGCGGTGAACAGTTCCTC
Sigma-Aldrich N/A
mmu-mir146a/b s
CACCGTCTGAGAACTGAATTCCAT
Sigma-Aldrich N/A
mmu-mir146a/b as
AAACATGGAATTCAGTTCTCAGAC
Sigma-Aldrich N/A
NTC s
CACCGTTCCGGGCTAACAAGTCCT
Sigma-Aldrich N/A
NTC as
AAACAGGACTTGTTAGCCCGGAAC
Sigma-Aldrich N/A
Itgb3 s
CACCGATTGAGTTCCCAGTCAGTG
Sigma-Aldrich N/A
Itgb3 as
AAACCACTGACTGGGAACTCAATC
Sigma-Aldrich N/A
Recombinant DNA
pMD2.G addgene Cat# 12259
psPAX2 addgene Cat# 12260
psiCHECK-2 Vector Promega Cat# C8021
LT3-GEPIR Fellmann et al., 2013 N/A
MSCV-Hoxa9-PGK-neo Kroon et al., 1998 N/A
MSCV-Meis1-IRES-YFP Pineault et al., 2003 N/A
pLentiCRISPRv2 Sanjana et al., 2014 N/A
Software and Algorithms
BioConductor v3.2 Huber et al., 2015 http://www.bioconductor.org
Bowtie2 v2.2.3 Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/bowtie2
DESeq2 v1.10.1 Love et al., 2014 http://www.bioconductor.org/packages/
release/bioc/html/DESeq2.html.
Gencode annotation vM7 Gencode https://www.gencodegenes.org/mouse_
releases/7.html
FastQC v0.11.4 Babraham Bioinformatics http://www.bioinformatics.babraham.
ac.uk/projects/fastqc/
GeneSpring 13.1 N/A http://www.genomics.agilent.com/article.
jsp?pageId=2141
ISMARA client v1.0.1 Balwierz et al., 2014 https://ismara.unibas.ch/ISMARA/client/
MACS2 v2.1.0 Zhang et al., 2008 https://github.com/taoliu/MACS
MaxQuant version v1.5.2.8 Cox and Mann, 2008 http://www.coxdocs.org/doku.php?id=
maxquant:common:download_and_installation
Perseus version v1.5.2.4 N/A http://www.coxdocs.org/doku.php?id=
perseus:common:download_and_installation
R v3.2.3 R Core Team, 2016 https://www.r-project.org
STAR v2.4.2a Dobin et al., 2012 https://github.com/alexdobin/STAR
UniProt human database UniProt http://www.uniprot.org/
Other
L-ARGININE:HCL (U-13C6, 99%; U-15N4, 99%) Euriso-top Cat# CNLM-539
L-Lysine:2HCl, ‘‘(13C6, 99%; 15N2, 99%)’’ Euriso-top Cat# CNLM-291
Publicly available data (Meis1 ChIP-seq) Gene Expression
Omnibus (GEO)
Cat# GSM842248, Cat# GSM842251
Titansphere 10mm, 500mg GL Science Cat# 5020-75010
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
LS Columns Miltenyi Biotec Cat# 130-042-401
C18 stage-tip Rappsilber et al., 2003 N/A
L-Prolin Roth Cat# 1713.2
dialyzed FCS Sigma-Aldrich Cat# F0392
L-Arginine Sigma-Aldrich Cat# A5006
L-Lysine dihydrochloride Sigma-Aldrich Cat# L5751
MethoCult GF M3534 Stemcell Technologies Cat# 03534
StemSpan SFEM Stemcell Technologies Cat# 09600, 09650
DMEM for SILAC Thermo Fisher Scientific Cat# 88420CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Thomas
Oellerich (thomas.oellerich@kgu.de).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All animal experiments were performed according to the regulations of the United Kingdom Home Office and German authorities.
Meis1tmloxP/tmloxP mice crossed to B6;129-Gt(ROSA)26Sortm1(Cre/ERT)Nat/J mice were obtained as previously described
(Miller et al., 2016) and maintained at the British Columbia Cancer Agency Animal Resource Centre (ARC) with all protocols
approved by the University of British Columbia Animal Care Committee (Certificate A13-0063). C57BL/6J mice for transplantation
experiments were obtained from Jackson Laboratory (Bar Harbor) and maintained at the Zentrale Forschungseinrichtung (ZFE)
of the Goethe University of Frankfurt. Donor (8-10 weeks) and recipient mice (10-12 weeks) were reared in groups of up to
5 mice per cage. Mice from transplantation assays were sacrificed after visible characteristics of AML. B6/miR-146a-/-
mice (8-10 weeks) (Boldin et al., 2011) were purchased from the Jackson Laboratory (Bar Harbor). All mice were female with
a weight >20g.
Cell Lines
293T (DSMZ), the ecotropic GP+E86 (ATCC) and Platinum-E (PlatE, Cell Biolabs) packaging cell lines were cultured in DMEM (Life
Technologies) with 10% heat-inactivated (h.i.) FCS (Sigma-Aldrich), 2 mM L-Glutamine (Lonza), 100 U/ml Penicillin and 100 mg/ml
Streptomycin (Life Technologies).
Primary Cells
Murine bone marrow cells were isolated by flushing femur and tibia of the hind legs of two to three mice. Bone marrow cells from
individual animals were pooled for further processing. Mouse bone marrow cells were cultured in DMEM with 10% h.i. FCS
(Sigma-Aldrich), 2 mM L-Glutamine (Lonza), 100 U/ml Penicillin and 100 mg/ml Streptomycin (Life Technologies) supplemented
with 10ng/ml murine recombinant IL3, 10 ng/ml human recombinant IL6, and 100ng/ml murine recombinant SCF (all Peprotech)
(Argiropoulos et al., 2008).
CD34+ mononuclear cells were isolated from human bone marrow aspirates. Bone marrow aspiration from healthy donors was
performed at the Institute of Transfusion Medicine and Immunohematology of Goethe University and German Red Cross Blood
Donor Service in Frankfurt. Use of the bone marrow aspirates for research purposes was approved by the Ethics Committee
of the University of Frankfurt (329-10) and donors gave written consent for use of the samples. Short term culture of CD34+
bone marrow cells from healthy donors was done in StemSpan Serum-Free Expansion Medium (SFEM, Stemcell Technologies)
supplemented with 100 ng/ml murine SCF, 100 ng/ml murine TPO, 100 ng/ml human FLT3-L and 100 ng/ml human IL6 (all
Peprotech).
Human Bone Marrow Biopsies
Bone marrow biopsies from 115 AML patients treated at the University Hospital Frankfurt, Germany, were obtained for histological
staining from the biobank of the local University Cancer Center. Use of the biopsies for research purposes was approved by the
Ethics Committee of the University of Frankfurt (SHO-04-2014). All patients gave written consent for use of their samples. Patient
characteristics are summarized in Table S2.Cancer Cell 31, 549–562.e1–e11, April 10, 2017 e5
METHOD DETAILS
Retroviral Infection of Lineage-Depleted Bone-Marrow Cells
Bone marrow cells were harvested from C57BL/6J or conditional Meis1 knockout mice, and lineage-negative cells were obtained by
negative selection using a Lineage Cell Depletion Kit (mouse) (Miltenyi Biotec) following themanufacturer’s instructions. 3-5x105 line-
age-negative cells were retrovirally infected with Hoxa9 alone or Hoxa9 andMeis1 by co-culture with 1x106 GP+E86 cells containing
MSCV-Hoxa9-PGK-neo (for 3 days) or MSCV-Meis1-IRES-YFP (for 1 day) in 2mlmedium in a 6-well plate in the presence of 10 mg/ml
polybrene (Sigma-Aldrich). Hoxa9 cells were selected with 0.6 mg/ml G418 (Sigma-Aldrich) for at least 5 days. After selection, cells
were sortedwith a FACSBDAria III cell sorter. Meis1 knock-out inMeis1fl/fl mice was induced by treatment with 4-hydroxy-tamoxifen
(4-OHT) (Sigma-Aldrich) at a final concentration of 100 nM.
Lentivirus Production and Lentiviral Transduction
VSV-G pseudotyped virus particles of CRISPR (pLentiCRISPRv2-BFP) or shRNA vectors (LT3-BEPIR) were produced by transient
transfection of subconfluent HEK293T cells with the packaging Plasmid psPAX2 (Addgene plasmid #12260) and the envelope
plasmid pMD2.G (Addgene plasmid #12259, both were a gift from Didier Trono) using calcium phosphate or polyethylenimine
(Bender et al., 2016). Ecotropic retrovirus for hSYK in the pRRL.PPT.SFFV.IRES.eGFP.wPRE vector was generated using the Plat-
inum-E (PlatE) packaging cell line (Cell Biolabs). After 36 and 60 hours, cell culture supernatants were collected, filtered (0.45 mm) and
viral particles were spun (1243xg, 30 min, 32C) onto 24-well cell culture plates which had been coated with RetroNectin (Takara Bio
USA Inc) before according to themanufacturer’s instructions. Finally, target cells were seeded and spun (200xg, 5min, 32C) onto the
virus-coated cell culture plate. To increase transduction efficiency of VSV-G pseudotyped lentivirus, cells were additionally treated
with concentrated virus which was enriched by ultracentrifugation (51610xg, 2 hours, 4C) in an OPTIMA XPN-80 ultracentrifuge
using the SW32 Ti rotor (Beckman Coulter GmbH). Transduced cells were selected with puromycin or fluorescence activated cell
sorting. shRNA expression in transduced cells was induced by addition of 1 mg/ml doxycyclin (Sigma-Aldrich) to the cell culture me-
dium. Of the hSYK transduced cells, cells with an approximately 3-fold increase of SYK expression were sorted by FACS.
XTT Viability/Proliferation Assay
Proliferation was assessed by XTT (sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium)
inner salt) assay: 5000 cells/well were seeded in regular growth medium in quadruplicate into 96-well plates. After seeding (day 0)
and on days 2 and 3, XTT reagent (Applichem) was added and absorption was measured after 4 h by using a Tecan Infinite
200Pro plate reader. Medium alone was used as blank.
Colony Formation Assay
Colony-forming cells (CFCs) were assayed in methylcellulose (Methocult M3534; StemCell Technologies Inc.) as described previ-
ously (Heuser et al., 2007). 100 cells were mixed with 1 ml methylcellulose and inhibitor or DMSO as control. Cells were incubated
at 37C under 5% (v/v) CO2. Colonies were evaluated microscopically 7 days after plating by using standard criteria. For replating,
cells were eluted from the methylcellulose, washed, counted and replated as described above.
Transplantation, Monitoring and Analysis of Animals
7.5x104 cells were transplanted together with 2x105 support cells by injection into the tail vein of lethally irradiated (9.5 Gy) recipient
mice (C57BL/6J). Support cells were isolated from C57BL/6J mice and purified on a Ficoll gradient (Sigma-Aldrich,).
After transplantation with the inducible shRNA-based Syk knock-down cells, mice were treated with doxycyclin as described in
(Zuber et al., 2011). The R788 treatment was performed as described in (Hahn et al., 2009).
Blood, spleen, liver and bone marrow were isolated from mice for further analysis. Blood counts were analyzed with ScilVet abc
animal blood cell counter (Scil Animal Care Company). Cells from spleen and bone marrow were incubated for 10 min with erythro-
cyte lysis buffer (155mMNH4Cl, 10mMKHCO3, 0.1mMEDTA) and then washed twice with 2%FCS in PBS. Staining was performed
with antibodies against the following cell surface markers: Gr-1, Mac-1, c-Kit, Sca-1 and CD19. 7-AAD was used as viability dye.
Blood smears and purified cells from bone marrow and spleen were centrifuged on object slides (2x105 cells/slide). Subsequently,
cells were fixed for 10 min with methanol and stained with a May-Gr€unwald solution for 8 min followed by Giemsa (both Merck
Millipore) staining for 20 min.
Parts of spleen and liver were fixed and stored in Roti-Histofix 4% (Roth) and subjected to routine HE staining and IHC for GFP/
YFP at the Histology-Core Facility of the Georg-Speyer-Haus, Frankfurt.
Primary human AML samples derived fromBMMNCswere depleted of CD3+ T lymphocytes and transplanted via tail vein injection
into 6-week-old NOD–Scid Il2rgnull (NSG) mice (Jackson Laboratory) conditioned with 200 cGy of gamma irradiation.
Isolation of CD34+ Mononuclear Cells from Human Bone Marrow Aspirates
Isolation of bone marrow mononuclear cells (BM-MNCs) from human bone marrow aspirates was achieved by Ficoll density centri-
fugation (400xg, RT, 45 min). CD34+ BM-MNCs were isolated using the human CD34 MultiSort Kit (Miltenyi Biotec) following the
manufacturer’s instructions. Briefly, BM-MNCs were washed twice with MACS buffer (PBS containing 0.5% bovine serum albumin
(BSA) and 2 mM EDTA), passed through a nylon mesh to remove cell clumps and incubated in MACS buffer supplemented with FcRe6 Cancer Cell 31, 549–562.e1–e11, April 10, 2017
Blocking Reagent and CD34MultiSort MicroBeads for 30 min at 4C. Excess MicroBeads were washed off and magnetic separation
was done manually using LS columns. After elution, cells were washed once in MACS buffer and resuspended in SFEM supple-
mented with diverse cytokines as described above. Purity of the isolated cells was verified by flow cytometry. For apoptosis
measurements, 2x104 cells were seeded in 100 ml culture medium and treated with DMSO (control), 1 mM, 5 mM and 10 mM R406
or PRT062607 for 24 hours. Annexin V staining was done as described below.
Flow Cytometry
For flow-cytometry, 2x105 cells were washed twice with 2% FCS in PBS and stained for 20 min at 4C in the dark with the following
antibodies: PerCP-Cy5.5-conjugated anti-mouse Gr1, V450-conjugated anti-mouse Mac1, APC-conjugated anti-mouse c-kit,
PE-Cy7-conjugated anti-mouse Sca1, PE-conjugated anti-mouse Fc 3RI, PE-conjugated anti-mouse/rat CD61 (Itgb3, all from
eBioscience), PE-conjugated anti-mouse CD51, BV421-conjugated anti-human CD34 and APC-H7-conjugated anti-mouse CD19
(both BDBioscience). Excess antibody was removed bywashing the cells at least twice with 2%FCS in PBS. 7-AAD (BD-Bioscience)
was used for dead-cell exclusion.
Generation of CRISPR Constructs
pLentiCRISPRv2 vectors (Sanjana et al., 2014) containing the different sgRNAs were obtained by target-specific oligonucleotide
annealing using the GoldenGate protocol. Oligonucleotide names and sequences (5’-3’) are listed in the key resource table. The
puromycin resistance cassette in pLentiCRISPRv2was replaced by blue fluorescent protein (BFP) using standard cloning techniques
to allow fluorescence activated cell sorting of transduced cells.
Generation of shRNA Constructs
Doxycycline-inducible lentiviral shRNA vectors were provided by Johannes Zuber (Research Institute of Molecular Pathology,
Vienna, Austria) (Fellmann et al., 2013). PU.1 knockdown was performed as described (Zhou et al., 2014). For the knockdown of
Syk inmouseBMcells, theGFP expression cassette under the Dox-inducible T3Gpromoter of the LT3-GEPIR vector was exchanged
to BFP by overlap PCR. The resulting vector was named LT3-BEPIR. The 97nt template hairpin oligos for shRNA cloning were de-
signed with the RNAi Central shRNA retriever tool (http://cancan.cshl.edu/RNAi_central/RNAi.cgi?type=shRNA) by providing the
accession number of mouse Syk, transcript variant 1 (NM_011518). The synthetic hairpin oligos served as templates for PCR ampli-
fication using the primer sequences for de novo generation of miR-E shRNAs (Fellmann et al., 2013). Finally, the shRNAs were cloned
into the LT3-BEPIR vector via the XhoI and EcoRI restriction sites. An LT3-BEPIR vector containing the non-targeting GL2 shRNA
against the Renilla Luciferase gene in the pGL2-basic cloning vector (GenBank X65323.2) was used as control. The sequences of
the template hairpin oligos used for cloning are listed below.
Immunohistochemistry
Tumor tissues were fixed and stained as described (Oellerich et al., 2015). Briefly, biopsy samples for histological stains were sliced
and stained with antibodies against HOXA9 (Novus Biologicals; dilution 1:500), MEIS1 (Abcam; dilution 1:2500), PU.1/Spi1 (Abcam;
dilution 1:200), SYK (Cell Signaling Technologies; dilution 1:100) and pY348-SYK (Abcam; dilution 1:100). Two independent pathol-
ogists performed evaluation of all tissue samples based on a three-level staining score (0 = negative; 1 =weakly positive; 2 = positive).
Overexpression of HOXA9, MEIS1, PU.1 and (p)SYK was defined by a score of 2.
Cell Cycle Analysis
Cell cycle analysis was performed using the BD Pharmingen APC BrdU Flow Kit (BD Bioscience) according to the manufacturer’s
protocol.
Briefly, 1x106 transducedmouse BM cells were cultured for 48h prior to labeling with 10 mMBrdU for 1 hour. Cells were harvested,
washed once with Staining Buffer (1x PBS supplemented with 3% h.i. FCS and 0.09% sodium azide) and incubated with Cytofix/
Cytoperm buffer for 15 min on ice. After washing with PermWash buffer, cells were permeabilized with Cytoperm Plus buffer for
10 min on ice, washed with PermWash buffer, incubated again in Cytofix/Cytoperm buffer for 5 min on ice followed by another
PermWash buffer washing step. BrdU epitopes were then exposed by treating the cells with 0.4 mg/ml DNase I for 1 hour at
37C. After removal of the DNase by washing the cells with PermWash buffer, they were incubated with 1 ml APC-conjugated
BrdU antibody in 50 ml PermWash buffer for 20min at RT in the dark. Subsequently, cells were subjected to a final PermWashwashing
step, resuspended in 20 ml 7-AAD and incubated for 5 min at RT in the dark. After addition of 1 ml Staining Buffer, cells were analysed
using a BD LSRFortessa flow cytometer.
Annexin V Staining
For detection of apoptotic cell death, the Annexin V Apoptosis Detection Kit I (BD Bioscience) was used according to the manufac-
turer’s instructions. Briefly, cells were harvested and washed once with PBS, resuspended in 200 ml 1x Annexin V binding buffer con-
taining 5 ml Annexin-PE or Annexin-APC and incubated for 15min at RT in the dark. After one washing with 1x Annexin binding buffer,
cells were resuspended in 1x Annexin V binding buffer containing 5 ml 7-AAD and incubated for 10min at RT in the dark. Finally, 200 ml
1x Annexin V binding buffer were added and cells were analysed using a BD LSRFortessa flow cytometer.Cancer Cell 31, 549–562.e1–e11, April 10, 2017 e7
RNA Isolation and Reverse Transcription
Cells were collected by centrifugation, washed once with PBS and lysed in Qiazol (Qiagen). RNA isolation was performed according
to the TRIzol reagent (Life Technologies) protocol. For gene expression analysis, RNA was treated with DNase to eliminate contam-
inating DNA using the Turbo DNA-free kit according to the manufacturer’s protocol (Ambion). For analyses of gene and pri-miR
expression, 250 ng RNA were reverse transcribed into cDNA using 5 mM Random Hexamers, 20 U RiboLock RNase inhibitor,
1mM of each dNTP and 200U RevertAid H Minus M-MuLV reverse transcriptase in a PCR machine (25C for 5 min, 42C for
60 min, 70C for 5 min) according to the RevertAid H Minus First Strand cDNA Synthesis Kit manual (Thermo Fisher Scientific).
cDNA synthesis for mature miRNA detection was done according to the TaqMan MicroRNA Assay protocol (Applied Biosystems).
RNA Sequencing and Data Analysis
RNA was extracted from five replicates (107 cells each) for each cell type (H, H/M and H/S) using the RNeasy Mini Kit (Qiagen) with
on-column DNase I digestion. RNA quality and quantity were assessed using an Agilent Bioanalyzer 2100 and RNA Nano Chips (Agi-
lent Technologies). RNA integrity numbers ranged between 9.7 and 10. Poly-A enrichment and preparation of sequencing libraries
was conducted with 1 mg total RNA from each sample using the NEB Next Ultra RNA Library Preparation Kit (NEB). Single-end
sequencing (75 bp) was conducted on a NextSeq500 (Illumina) following standard procedures. The average read counts per group
were: H: 22.5M (SD: 1.2M); H/M: 22.1M (SD: 0.3M), H/S: 23.2M (SD:1.4M). Read alignment to themouse genome reference sequence
GRCm38/mm10 was performed using STAR v2.4.2a (Dobin et al., 2012). Differential gene expression analysis was conducted using
DESeq2 v1.10.1 (Love et al., 2014).
Immunoblotting
Lysis of cells was performed with NP40-containing lysis buffer (150 mM NaCl, 50 mM Tris at pH 7.5–7.8, 5 mM NaF, 0.5% NP40,
1 mM sodium vanadate, Complete protease inhibitor cocktail (Roche) for 10 min on ice followed by centrifugation to remove cell
debris. For nuclear proteins, NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific) were used accord-
ing to the manufacturer’s protocol. Protein concentrations were determined with the Pierce BCA Protein Assay Kit (Thermo Fisher
Scientific). Proteins were separated on precast 4–15%Mini Protean TGX gels at 190 V using theMini Protean electrophoresis system
and TGS buffer and were blotted onto nitrocellulose membranes at 70V for 2 h in a Mini Trans-Blot Cell by using the TG buffer sup-
plemented with 20% methanol (all BioRad). All antibodies were used as recommended by the manufacturer.
Dual luciferase Assay
Synthetic oligonucleotides containing the two miR-146a binding sites from the mouse Syk 30-UTR or mutated versions thereof in
duplicate, all ending with XhoI and NotI restriction sites, were annealed and cloned into the PsiCheck-2 dual luciferase vector
(Promega). Additionally, a dual luciferase vector comprising the complete mouse Syk 30-UTR was used (Genecopoeia). For the
dual luciferase assays, HEK293T cells were seeded in 24-well plates and co-transfected with 0.2 ng dual luciferase vector and 20
pmol Pre-miR control or miR-146a precursor (Ambion) using Lipofectamine 2000 (Invitrogen). 48h after transfection, cells were lysed
and firefly and renilla luciferase activities were measured with the Dual-Luciferase-Assay System (Promega) according to the man-
ufacturer’s protocol on a Tecan Infinite 200Pro plate reader.
miRNA Expression Profiling
Expression analysis of miRNAs was performed using an Affymetrix GeneChip miRNA 3.0 array. miRNAs were isolated with the
miRNeasy Kit (Qiagen). Data analysis was performed using GeneSpring 13.1. Raw data were processed with the RMA algorithm
and normalized by quantile normalization. miRNAs with expression values below the 20th percentile were removed. A difference
in expression between Hoxa9 and Hoxa9/Meis1 cells was considered statistically significant if q value <0.01 (moderated t-test
and Benjamini-Hochberg multiple testing correction) and absolute log2 fold change >1.
Chromatin Immunoprecipitation
ChIP was performed by using the ChIP-IT Express Kit (Active Motif) according to the manufacturer’s instructions. Briefly, 2x107 H
and H/M cells, respectively, were fixed withmethanol-free formaldehyde (Life Technologies) at a final concentration of 1% for 10min.
After neutralization with glycine, cells were lysed in lysis buffer with protease inhibitors and nuclei were prepared according to the
manufacturer’s instructions (Covaris). Samples were sonicated to an average DNA length of 200–400 bp with a M220 Focused-ultra-
sonicatorTM (Covaris). ChIP was carried out using 5 mg of anti-PU.1 antibody (Santa Cruz) or rabbit IgG (Santa Cruz), respectively.
DNA was purified with IPure kit (Diagenode) and target regions were assessed by qPCR.
Quantitative PCR Analysis
MouseSyk,Spi1/PU.1 andMeis1were detectedwith commercial TaqManGene Expression assays (AppliedBiosystems). GAPDHwas
used for normalization. Human HOXA9 and MEIS1 expression was measured with SYBR Green and normalized to a-actin using the
primers listed in theKeyResourcesTable. qPCRexpressiondatawerenormalizedusing theDDCTmethod (LivakandSchmittgen,2001).e8 Cancer Cell 31, 549–562.e1–e11, April 10, 2017
miRNA expression was measured using TaqMan MicroRNA Assays designed for mmu-miR-146a (Applied Biosystems) according
to themanusfacturer’s protocol. Sno202 served as endogenous control. For detection ofmiRNA primary transcripts (Pri-miR), a com-
mercial TaqMan Gene Expression Assays for mmu-miR-146a (Applied Biosystems) was used and GAPDH served as endogenous
control.
Quantitative PCR for confirmation and quantitation of Meis1 knock-out in Meis1fl/fl mice was performed as previously described
(Miller et al., 2016) using a primer-set NDF for detection of non-deleted floxed Meis1 and a control primer-set detecting a region
in exon 7 of Meis1. PCR was performed using SYBR Green (Applied Biosystems) and analyzed using the DDCT method.
Quantitative PCR for the DNA from chromatin immunoprecipitation was performed using SYBRGreen (Bio-Rad) for a region -10kb
upstreamofmiR-146a, a positive control locus at -13.7kb upstream of the PU.1 transcription start site and a negative control region in
exon9 of FLT3. PU.1 and IgG binding were normalized to input control using the DDCT method (Livak and Schmittgen, 2001). The
primer sequences are listed in the Key Resources Table.
Time-lapse Microscopy and cell Tracking
Time-lapse microscopy and tracking of H and H/M cells in the presence or absence of the SYK inhibitor R406 (500 nM) was per-
formed as previously described (Haetscher et al., 2015; Rieger et al., 2009) until the fate of the cell (death or division) was determined.
The time point of death was calculated from the beginning of themovie until the cell died. Dead cells were depicted by their shrunken,
non-refracting and immobile appearance. The cell death proportion is calculated based on the number of cells in each generation that
undergo either division or death. Cell tracking was carried out manually.
SILAC Labeling
SILAC-labeling was performed with SILAC DMEM (Thermo Fisher Scientific) supplemented with 10% h.i. dialyzed FCS (Sigma-
Aldrich), 100 U/ml Penicillin, 100 mg/ml Streptomycin (Life Technologies) and heavy amino acid isotopes (13C6
15N4L-arginine and
13C6
15N2L-Lysine) (Cambridge Isotope Laboratories) or regular (light) amino acids (
12C6
14N4L-arginine and
12C6
14N2L-Lysine,
Sigma-Aldrich).
Phospho-peptide Enrichment and Mass Spectrometry
Antibody-based enrichment for tyrosine-phosphorylated peptides (pYome) was performed using the PTMScan Phospho-Tyrosine
rabbit mAB (P-Tyr-1000) Kit as described in the manufacturer’s instructions (Cell Signaling Technology) and according to Rush
et al (Rush et al., 2005).
Briefly, SILAC-labeled protein lysates were mixed in equimolar amounts and proteins were reduced with DTT and alkylated with
IAA. The urea concentration was lowered to 2Mwith 20mMHEPESbefore overnight digestionswith trypsin. Resulting peptideswere
purified with Sep-Pak tC18 cartridges and lyophilized. Immunoprecipitation was performed with the anti-phosphotyrosine-specific
antibody P-Tyr-1000 (Cell Signaling Technology). Peptides were eluted under acidic conditions from the beads and purified with
STAGE-Tips.
For the enrichment of the global phosphoproteome (GPome), equimolar mixed, SILAC-labeled proteins were precipitated with
acetone. The pellet was dissolved in 1% RapiGest Surfactant (w/v). Proteins were reduced at a final concentration of 10 mM DTT
for 1 h at 65C and reduced with CAA at a final concentration of 20 mM for 1 h at 37C. Proteins were digested with trypsin in the
presence of 0.1% RapiGest at 37C overnight. For RapiGest degradation the digest was acidified to 1% TFA and incubated for
2 h at 37C. RapiGest precipitations were cleared by centrifugation with max. rpm at RT. The peptide containing supernatant was
dried in a SpeedVac concentrator. Peptides were fractionated by strong cation exchange (SCX) as described by Gruhler et al.
with some modifications (Gruhler et al., 2005).
Briefly, SCX chromatography was performed on a FPLC system (SMART, Pharmacia) using an ammonium formate based buffer
system. Buffer A had a final concentration of 10mMammonium formate and buffer B had a final concentration of 500mM ammonium
formate both at pH 2.7 and containing 30% ACN (v/v). 20 Fractions were collected over a 50 min gradient with a flow rate of
100 mL/min. The first twelve fractions were dried in a SpeedVac concentrator and subsequently used for phospho-peptide enrich-
ment or stored at -20C until use. The following TiO2 spin column phosphopeptide enrichment was performed with minor modifica-
tions as described by Larsen et al. (Larsen et al., 2005). Dried peptides were suspended by intensive vortexing and sonication in 60 mL
of loading solution. All following centrifugation steps were performed with 3000 rpm at RT for 5 min. In-house made titanium dioxide
spin columns were equilibrated with 60 mL of loading solution followed by sample loading. Phosphopeptides bound to TiO2 beads
were washed three times with 60 mL loading solution and five times with 60 mL washing solution. Phosphopeptides were eluted
with a 0.6 N solution of NH4OH (pHR 10.5), dried in a SpeedVac concentrator and stored at -20
C until mass spectrometric analysis.
Phosphorylated peptides were analyzed on an EASY n-LC 1000 (Thermo Scientific) coupled to a hybrid quadrupole-Orbitrap mass
spectrometer (Q Exactive, Thermo Scientific). Peptides were separated on an analytical column (75 mm x 200 mm, ReproSil-Pur 120
C18-AQ, 3 mm, Dr. Maisch GmbH, packed in-house) using a 90 min (GPome) or 120 min (pYome) linear gradient, respectively. The Q
Exactive was operated in a DDA selecting the twelve most abundant precursors for HCD fragmentation in the collision cell with an
isolation window of 2 m/z and a NCE of 28.
Raw files were processed with MaxQuant v1.5.0.25 against the UniProtKB/Swiss-Prot mouse database (downloaded July 2014).
Cysteine carbamidomethylation was set as fixed modification, methionine oxidation and serine, threonine and tyrosine phosphory-
lation for both the pYome and the global phosphoproteome dataset as variable modification. The ‘Minimum Andromeda Score’ andCancer Cell 31, 549–562.e1–e11, April 10, 2017 e9
‘Delta score’ for modified peptides was set to 40 and 6, respectively. The following parameters were applied: the MS1 first search
peptide tolerance was set to 20 ppm and the main search peptide tolerance to 4.5 ppm. The FTMS MS/MS tolerance was set to
20 ppm, a false discovery rate (FDR) of 1% for peptide spectrummatches (PSM), protein and site decoy was applied. The ‘Re-quan-
tify’ option of MaxQuant was enabled. Unique, razor, unmodified, N-terminally acetylated and M oxidized peptides were used for
protein quantitation and the minimum ratio count required was set to 2.
For protein expression analysis, SILAC-labeled H and H/M cell lysates weremixed in a 1:1 ratio. A total of 100 mg protein was sepa-
rated by SDS-Page using pre-cast Bis-Tris minigels (NuPAGENovex 4–12%, Life Technologies) and visualised by staining with Coo-
massie Brilliant Blue (Serva). Each lane was cut into 23 slices, reduced with dithiothreitol (DTT, Sigma-Aldrich) and alkylated with
iodoacetamide (IAM, Sigma-Aldrich), digested in-gel with trypsin (Serva), extracted and analysed by mass spectrometry as
described in (Corso et al., 2016).
QUANTIFICATION AND STATISTICAL ANALYSIS
Proteome Data Analysis
The MS raw files were processed by MaxQuant (Cox and Mann, 2008) (version 1.5.2.8) and MS/MS spectra were searched against
UniProt human database (downloaded on Feb, 2015; 89,796 entries) via the Andromeda search engine (Cox et al., 2011). Mass toler-
ance after recalibration of precursor mass and fragment ion mass were set as 6 and 20 ppm, respectively. Allowed variable modi-
fications included protein deamidation (N), oxidation (M) and phosphorylation (STY). Cysteine carbamidomethylation was defined
as a fixed modification. Minimal peptide length was set to 7 amino acids with the maximum of two enzymatic mis-cleavages. The
false discovery rate (FDR) was set to 1% for both peptide and protein identifications. Intensities of all identified peptides were deter-
mined by MaxQuant with options ‘‘match between runs’’ and ‘‘re-quantify’’.
Subsequent data analysis was conducted with Perseus (version 1.5.2.4). After removing all decoy hits and potential contaminant
entries, identified phosphosites with localization probability smaller than 0.75 were filtered out. All SILAC ratios were log2 trans-
formed and those with absolute log2 Z score >1 were considered significantly regulated.
RNA-seq data Analysis
Data quality control was performed with FastQC v0.11.4 and revealed no appreciable technical artefact. Reads were aligned to the
mouse reference genome (mm10, Ensembl GRCm38 release 82) using STAR v2.4.2a (Dobin et al., 2012), clipping the first 5 nucle-
otides (–clip5pNbases 5). Gene count tables were generated while mapping, using Gencode vM7 annotations. All downstream an-
alyses were carried out using R v3.2.3 (R Core Team, 2016) and BioConductor v3.2 (Huber et al., 2015). Exploratory analyses and
differential gene expression analysis were carried out with DESeq2 v1.10.1 (Love et al., 2014). For sample clustering and principal
component analysis, genes with zero counts across all samples were removed from the analysis. For differential expression analysis,
theWald test was used for pairwise comparisons, whereas a likelihood ratio test was used to extract significant differences across all
three conditions.
Motif Activity Analysis
Motif activity analysis was performed using the standalone ISMARA (Integrated System for Motif Activity Response Analysis) client
(Balwierz et al., 2014). For this analysis, reads were aligned to the mm9 mouse reference genome (GRCm37) using STAR as
described above. ISMARA profiles were averaged by taking into account the experimental design.
ChIP-seq data Analysis
Meis1 ChIP-seq data from (Huang et al., 2012) were retrieved from the Short Read Archive (SRA) and aligned to the mouse reference
genome (mm10) using Bowtie2 (Langmead and Salzberg, 2012) with standard parameters. Peaks were called using MACS2 v2.1.0
(Zhang et al., 2008) using a q-value threshold of 0.05. The peak union from two biological replicates was used for the analysis.
AML patient Survival Analysis
For AML patients time-to-event data were observed using Kaplan-Meier analysis with survival end point definitions as described in
(Cheson et al., 2003). For quantitative assessment hazard ratios and 95% confidence intervals (CIs) of hazard ratios were computed
based on Cox proportional hazards model. Significant survival association was assessed using the log-rank test. Time-to-event data
was analyzed using the R ’survival’ package (version 2.38). Statistical analyses were performed in R (version 3.2.2). A two-sided
p value < 0.05 was considered significant.
hSyk Expression
To quantify the expression of human Syk (hSyk) in H/S cells, the sequence of the lentiviral construct containing the hSyk cDNA
was used to create a Bowtie2 index. RNA-seq reads were then aligned to this index using Bowtie2, allowing no mismatch in a
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DATA AND SOFTWARE AVAILABILITY
Data Resources
Mass spectrometry data (PRIDE: PXD004192) have been deposited to the PRIDE Archive. RNA-seq data (SRA: PRJNA322136)
have been deposited to the Short Read Archive. miRNA microarray data (GEO: GSE74566) have been deposited to the NCBI
Gene Expression Omnibus.
Software
Software programs used in this study were from publicly available resources. Please refer to Key Resources Table for more details.Cancer Cell 31, 549–562.e1–e11, April 10, 2017 e11
